Literature DB >> 33753246

Celastrol in metabolic diseases: Progress and application prospects.

Shaohua Xu1, Yaqian Feng2, Weishen He3, Wen Xu1, Wei Xu4, Hongjun Yang5, Xianyu Li6.   

Abstract

Metabolic diseases are becoming increasingly common in modern society. Therefore, it is essential to develop effective drugs or new treatments for metabolic diseases. As an active ingredient derived from plants, celastrol has shown great potential in the treatment of a wide variety of metabolic diseases and received considerable attention in recent years. In reported studies, the anti-obesity effect of celastrol resulted from regulating leptin sensitivity, energy metabolism, inflammation, lipid metabolism and even gut microbiota. Celastrol reversed insulin resistance via multiple routes to protect against type 2 diabetes. Celastrol also showed effects on atherosclerosis, cholestasis and osteoporosis. Celastrol in treating metabolic diseases seem to be versatile and the targets or pathways were diverse. Here, we systematically review the mechanism of action, and the therapeutic properties of celastrol in various metabolic diseases and complications. Based on this review, potential research strategies might contribute to the celastrol's clinical application in the future.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Application limitations; Celastrol; Celastrol (PubChem CID: 122724); Mechanisms; Metabolic diseases; Targets

Mesh:

Substances:

Year:  2021        PMID: 33753246     DOI: 10.1016/j.phrs.2021.105572

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  10 in total

1.  Celastrol inhibits laser-induced choroidal neovascularization by decreasing VEGF induced proliferation and migration.

Authors:  Zhen Li; Ke-Wen Zhou; Fang Chen; Fu Shang; Ming-Xing Wu
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

2.  Celastrol inhibits the proliferation and migration of MCF-7 cells through the leptin-triggered PI3K/AKT pathway.

Authors:  Pingping Chen; Bin Wang; Meng Li; Chunxue Cui; Fei Liu; Yonggang Gao
Journal:  Comput Struct Biotechnol J       Date:  2022-06-20       Impact factor: 6.155

3.  Effect of Celastrol on LncRNAs and mRNAs Profiles of Cerebral Ischemia-Reperfusion Injury in Transient Middle Cerebral Artery Occlusion Mice Model.

Authors:  Jiandong Liu; Xiangna Guo; Lu Yang; Tao Tao; Jun Cao; Zexuan Hong; Fanning Zeng; Yitian Lu; Chunshui Lin; Zaisheng Qin
Journal:  Front Neurosci       Date:  2022-05-23       Impact factor: 5.152

4.  Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment.

Authors:  Qingsi Wu; Jiading Wang; Yuanfang Wang; Ling Xiang; Yulu Tan; Jiaxing Feng; Zhirong Zhang; Ling Zhang
Journal:  Nano Res       Date:  2021-12-12       Impact factor: 10.269

5.  Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition.

Authors:  Shaohua Xu; Ruolan Fan; Lu Wang; Weishen He; Haixia Ge; Hailan Chen; Wen Xu; Jian Zhang; Wei Xu; Yaqian Feng; Zhimin Fan
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

6.  Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect.

Authors:  Piao Luo; Qian Zhang; Tian-Yu Zhong; Jia-Yun Chen; Jun-Zhe Zhang; Ya Tian; Liu-Hai Zheng; Fan Yang; Ling-Yun Dai; Chang Zou; Zhi-Jie Li; Jing-Hua Liu; Ji-Gang Wang
Journal:  Mil Med Res       Date:  2022-05-20

7.  Covalent Inhibition of Pyruvate Kinase M2 Reprograms Metabolic and Inflammatory Pathways in Hepatic Macrophages against Non-alcoholic Fatty Liver Disease.

Authors:  Ni Fan; Xiuying Zhang; Wei Zhao; Jia Zhao; Dan Luo; Yilu Sun; Ding Li; Chenliang Zhao; Yu Wang; Hongjie Zhang; Jianhui Rong
Journal:  Int J Biol Sci       Date:  2022-08-15       Impact factor: 10.750

Review 8.  Celastrol: A Promising Agent Fighting against Cardiovascular Diseases.

Authors:  Zhexi Li; Jingyi Zhang; Xulei Duan; Guoan Zhao; Min Zhang
Journal:  Antioxidants (Basel)       Date:  2022-08-18

9.  Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo.

Authors:  Qiang Xu; Guiping Chen; Huaen Xu; Guoming Xia; Meisong Zhu; Haibo Zhan; Bin Zhang; Min Dai; Hongxian Fan; Xuqiang Liu
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

10.  Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion.

Authors:  Dan-Dan Liu; Piao Luo; Liwei Gu; Qian Zhang; Peng Gao; Yongping Zhu; Xiao Chen; Qiuyan Guo; Junzhe Zhang; Nan Ma; Jigang Wang
Journal:  J Neuroinflammation       Date:  2021-08-09       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.